Evaxion Biotech AS
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.7504
- Today's High:
- $0.801
- Open Price:
- $0.8
- 52W Low:
- $0.92
- 52W High:
- $3.18
- Prev. Close:
- $0.781
- Volume:
- 75048
Company Statistics
- Market Cap.:
- $40.45 million
- Book Value:
- 0.344
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -50.78%
- Return on Equity TTM:
- -113.74%
Company Profile
Evaxion Biotech AS had its IPO on 2021-02-05 under the ticker symbol EVAX.
The company operates in the Healthcare sector and Biotechnology industry. Evaxion Biotech AS has a staff strength of 63 employees.
Stock update
Shares of Evaxion Biotech AS opened at $0.8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.75 - $0.8, and closed at $0.79.
This is a +0.73% increase from the previous day's closing price.
A total volume of 75,048 shares were traded at the close of the day’s session.
In the last one week, shares of Evaxion Biotech AS have slipped by -3%.
Evaxion Biotech AS's Key Ratios
Evaxion Biotech AS has a market cap of $40.45 million, indicating a price to book ratio of 3.8052 and a price to sales ratio of 0.
In the last 12-months Evaxion Biotech AS’s revenue was $0 with a gross profit of $0 and an EBITDA of $-24907000. The EBITDA ratio measures Evaxion Biotech AS's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Evaxion Biotech AS’s operating margin was 0% while its return on assets stood at -50.78% with a return of equity of -113.74%.
In Q1, Evaxion Biotech AS’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Evaxion Biotech AS’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evaxion Biotech AS’s profitability.
Evaxion Biotech AS stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.3219. Its price to sales ratio in the trailing 12-months stood at 0.
Evaxion Biotech AS stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $-64809000.00
- Total Liabilities
- $0
- Operating Cash Flow
- $0
- Capital Expenditure
- $440000
- Dividend Payout Ratio
- 0%
Evaxion Biotech AS ended 2024 with $-64809000.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $-64809000.00 while shareholder equity stood at $-78722000.00.
Evaxion Biotech AS ended 2024 with $0 in deferred long-term liabilities, $0 in other current liabilities, in common stock, $-78722000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.24 million and cash and short-term investments were $10.24 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Evaxion Biotech AS’s total current assets stands at $10.24 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2024, Evaxion Biotech AS's operating cash flow was $0 while its capital expenditure stood at $440000.
Comparatively, Evaxion Biotech AS paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.79
- 52-Week High
- $3.18
- 52-Week Low
- $0.92
- Analyst Target Price
- $10.67
Evaxion Biotech AS stock is currently trading at $0.79 per share. It touched a 52-week high of $3.18 and a 52-week low of $3.18. Analysts tracking the stock have a 12-month average target price of $10.67.
Its 50-day moving average was $1.08 and 200-day moving average was $1.41 The short ratio stood at 2.92 indicating a short percent outstanding of 0%.
Around 4247.3% of the company’s stock are held by insiders while 40% are held by institutions.
Frequently Asked Questions About Evaxion Biotech AS
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.